The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability. The first study of SCT costs, however, was not published until 1989. This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma. Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues. Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences. Keywords: cost-effectiveness, economics, stem cell transplantation The field of blood and bone marrow transplantation (stem cell transplantation, SCT) has changed dramatically over the past 10 years. Major advances in SCT technology has led to improved outcomes and wider availability. Numbers of SCT have increased from less than 5000 to more than 40 000 annually, and hundreds of papers related to SCT have been published.
The field of blood and bone marrow transplantation (stem cell transplantation, SCT) has changed dramatically over the past 10 years. Major advances in SCT technology has led to improved outcomes and wider availability. Numbers of SCT have increased from less than 5000 to more than 40 000 annually, and hundreds of papers related to SCT have been published. 1 Yet relatively few studies have addressed the costs and cost-effectiveness of this complex technology, although perceived high costs contribute to the controversy over its use.
The first comprehensive study of the costs of SCT was reported in 1989 and indicated that, while allogeneic bone marrow transplantation for patients with acute myelogenous leukemia (AML) was very costly, it was more cost-effective than chemotherapy. 2 In the past 3 years, with physicians facing increased economic pressures in the United States and abroad, many more studies have included economic analyses. These studies report markedly lower costs of SCT than in 1989 and even more favorable cost-effectiveness profiles for persons with hematological malignancies. In this paper, we provide an overview of economic analyses in general and subsequently summarize studies of costs of SCTs for leukemia and lymphoma.
Because the studies we review were conducted utilizing various methodologies and make numerous, differing assumptions regarding cost and clinical parameters, we begin our paper with a proposed framework for reviewing cost analyses (Section 1). We then review some of the 'issues' that our framework highlights, based on the work of others in the field (Section 2).
3-8 Section 3 begins with a table summarizing the current literature on costs of SCT using the framework developed in Section 1. Section 3 also discusses the more current, well-designed/presented studies, highlighting the authors' conclusions. Section 4 presents some additional issues to be considered in cost analyses of SCT.
A framework for comparing cost studies
There is growing attention to the costs and cost-effectiveness of medical interventions. Review of the sizable body of literature devoted to the topic reveals conflicting definitions of cost as well as discrepant methods for conducting and reporting studies. The work of the Panel on Cost-Effectiveness in Health and Medicine [5] [6] [7] [8] represents a consensus of field leaders, convened by the US Public Health Service, on guidelines for conducting studies as well as a format for presenting results. The Panel's recommendations were recently published in JAMA. [5] [6] [7] We used these guidelines and similar work by others to develop a framework for reviewing cost studies in SCT (Table 1) . [3] [4] [5] [6] [7] [8] While some of the standardization advocated in this and other papers may still be the subject of discussion, at a minimum, Table 1 provides a unifying framework with which one may compare studies. Once the salient aspects of a study are presented and/or compared, the reader can conduct his or her own evaluation of the weight of the findings. 
Issues in cost analyses
A number of items discussed in Table 1 require some clarification and/or discussion because of lack of consensus regarding standards, their misuse in the literature, or simply because of their controversial nature.
Type of analysis
The term cost-effectiveness research is often used to describe any study which looks at costs. Cost-effectiveness studies, however, are only those which look at both costs and outcomes (ie the 'effectiveness' part of 'costeffectiveness').
Other studies which examine only the costs associated with an intervention (typically because the interventions do not have significant differences in outcomes) would be considered cost-minimization or cost-identification studies. Cost-minimization studies can be informative if significant differences in outcomes are not expected or if outcome information is not yet available. Authors should be careful, however, to state clearly the type of analysis that they are conducting as well as the (potential) limitations of their approach.
Studies which attempt to quantify both the benefits and the costs of an intervention in terms of dollars are typically referred to as cost-benefit studies. Given the difficulties associated with assigning dollar values to life and quality of life, however, this type of analysis is usually reserved for the evaluation of major programs such as populationbased screening or immunization.
Perspective of analysis
The perspective of a cost analysis determines the relevant costs to consider. For example, when thinking about the costs of various types of cancer treatment, one could consider the costs from the perspective of the patient (lost work time, travel costs to the physician and hospital, health insurance copayments), of the employer (lost employee productivity, increased insurance premiums), of the insurance company (payments for physician visits, hospital stay, pharmaceuticals), or of society (costs to patients, employers, physicians and anyone else in society). The advantage of conducting the cost analysis from the perspective of society is that it takes into account all of the costs stemming from the treatment choice. This is especially important when the cost savings which accrue to one member of society as a result of employing one type of treatment impose costs on another member of society. For example, discharging a patient from hospital more quickly may significantly reduce the costs faced by an insurer but may impose significant costs on the patient and his or her caregiver. Conducting a cost analysis from a societal perspective allows a researcher to consider these tradeoffs explicitly. This perspective is advocated by the Panel on Cost-Effectiveness in Health and Medicine. 5, 7 Researchers who do not present their results from the societal perspective should provide an explanation of why an alternative perspective was chosen and the potential implications of this alternative for the results. Unfortunately, since many (if not most) of the economic studies of SCT are conducted retrospectively, it is difficult, if not impossible, to collect data on anything other than direct medical costs. In fact, all of the papers presented in subsequent sections restrict their analysis to direct medical costs, and, therefore, are not conducted from the societal point of view. While this information is still extremely useful, especially for the internal budgeting process of providers, considering the impact of other costs could expand the applicability of findings.
Types of costs
Costs associated with a treatment or intervention are usually broken down into three main categories: direct medical costs, direct non-medical costs and indirect costs. Gold Direct non-medical costs include those costs directly associated with treatment which are non-medical in nature; transportation and parking costs or the cost of special meals are examples of direct non-medical costs. While most researchers quickly acknowledge the relevance of these costs, relatively few cost analyses contain these direct nonmedical costs because the data are not often collected. Gold et al 5 point out that omission of these costs may lead to significant bias in results. Direct non-medical costs should only be omitted if there is strong a priori evidence that these costs are not likely to differ across arms of the study.
Indirect costs include those costs which are not directly attributable to the treatment but may be the result of the condition or the treatment. Work time lost by patient and caregiver and productivity losses due to morbidity are examples of indirect costs. Because indirect costs are also reflected in differences in utility of various health states, researchers must be careful not to 'double count' indirect costs. The inclusion of indirect costs in the numerator (ie as a financial cost) rather than the denominator (ie as a difference in quality-adjusted life years (QALYs)) of the cost-effectiveness ratio is the subject of significant controversy. Gold et al 5 present strong arguments for the inclusion of indirect costs in the denominator (ie as differences in quality adjusted outcomes). This approach avoids the somewhat subjective assignment of dollar values to these types of costs and explicitly considers patient valuation of these costs.
Inclusion of costs other than direct medical costs in SCT cost analyses is relatively uncommon because the analyses tend to be retrospective, hindering reliable collection of direct non-medical and indirect costs. While future studies should focus on attempting to quantify these costs, current studies, at a minimum, should discuss the impact of omitting these costs and, if possible, provide reasonable estimates concerning their magnitude.
Methods of data collection
Techniques for the collection of health resource utilization data (eg hospital bed days, laboratory tests, pharmaceuticals) vary widely. Cost analyses in randomized controlled trials (RCTs) typically include extensive primary data collection during the course of treatment or retrospective chart review. The shortcoming of this approach is that researchers generally do not track costs beyond the initial treatment period. In addition, many researchers and clinicians complain that protocols for RCTs are substantially different from community practice and, therefore, are not a good reflection of 'real world' costs. Analyses of secondary data (ie insurance claims or hospital billing data) provide better longitudinal 'real world' data than a typical RCT. Unfortunately, this type of analysis must contend with potential selection bias resulting from non-random assignment of patients to treatment groups. A third method of data collection, using a patient diary in which the patient records the dates and types of care received, is sometimes used to supplement other collection efforts. The major obstacle associated with this type of data collection is the problem of accurate patient recall. There is some evidence, however, that patient recall accuracy is relatively high for periods of up to 3 months, with measures of agreement (kappa) between patient reports and medical charts as high as 88-96%. [9] [10] [11] [12] [13] Gold et al 5 acknowledge the advantages and disadvantages of each of these three methods of data collection and seem to advocate the approach or combination of approaches which most 'cost effectively' provides sufficient, accurate and unbiased data. Authors presenting cost analyses should clearly outline their data collection methods, discussing any limitations clearly.
An additional issue to be considered when collecting direct cost data is the method of cost attribution. Although charge data for medical care utilization are quite often available, these data usually differ from actual underlying costs. This discrepancy occurs for at least two reasons:
(1) Charges set by health care providers are often based on the average cost of providing a good or service rather than the marginal cost (ie the incremental increase in cost as a result of a one unit increase in output) because average cost is far easier to calculate. Marginal cost, however, is the more accurate measure of true opportunity cost. Opportunity costs are important from a societal point of view because they represent the cost of not using those same resources for the next best alternative (whatever that may be). The difference between average and marginal cost is particularly extreme in hospitals where large fixed costs create a significant gap between the average cost of treating a patient and the marginal cost. An example of this would be to consider the cost of increasing a patient's length of stay by 1 day. Although the hospital typically charges $800-$1200 for that day because this is similar to the average cost of a hospital day, the marginal costs of caring for that patient for 1 day, particularly 1 day at the end of his/her stay, are probably closer to $200-$400. Since this difference is less extreme in the physician office setting, several researchers argue that it is more acceptable to use charges to estimate the cost of outpatient services. (2) Charges are not determined by costs alone. They are also influenced by market conditions. If a hospital is in a relatively competitive market, it is conceivable that its prices would more closely reflect underlying cost. In a relatively uncompetitive market, however, charges may significantly exceed costs as hospitals exercise their market power.
It is necessary, therefore, in many studies to find alternatives to charge data when attributing cost. One of the most popular methods for attributing costs has been the ratios of costs to charges (RCCs). Since any hospital obtaining reimbursement from Medicare must submit RCC data on their Medicare patients (determined through a relatively standardized method), many researchers have used these data to translate charges into costs. A major criticism of this approach is that these data are based only on Medicare patients, and, depending on the population of the particular study, this may introduce significant bias. In addition, some argue that the methodology required by Medicare for allocating various costs to individual cost centers is outdated and inconsistent with the study's objective of measuring opportunity costs.
An alternative to using Medicare RCC data is to use internal RCC data derived from the individual institution's cost accounting data. These data are for all patients treated at a particular facility, are often far more detailed (by department) than the Medicare data, and some would argue that these data can more closely reflect the opportunity cost of goods/services provided. The major difficulty in using these data is that methods for allocating costs may differ among institutions, introducing unwanted heterogeneity in cost estimates.
A more general criticism of using RCC data to attribute costs is that differences in costs across institutions may reflect differences in efficiencies across these sites. Researchers must then address the question of 'What are true costs?' Are we interested in what it costs, on average, at the set of institutions studied, or do we try to present estimates of the most efficient cost? Should we present cost data which reflects (potential) inefficiencies or present costs based on the most efficient production of goods and services?
One method which avoids some of these 'inefficient provider' problems is the use of relative value units (RVUs) to attribute costs. Relative value units are units of value assigned to each medical procedure based on the resources (labor, capital equipment, office space, etc) used to produce that procedure. One of the most popular RVU scales is the Resource Based Relative Value Scale (RBRVS) developed by Hsiao and colleagues 14 which serves as the basis for Medicare Part B reimbursement of physicians. RVUs are translated into prices or costs by multiplying by a dollar conversion factor. For example, if procedure 1 has an RVU of 1 and procedure 2 has an RVU of 2.5, using a conversion factor of $20, procedure 1 would cost $20, while procedure 2 would cost $50. Although the conversion factor is subject to debate, the relative relationship(s) of procedure costs is unaffected. In the above example, procedure 2 is 2.5 times more expensive than procedure 1 no matter what type of conversion factor is used. While the use of RVUs avoids problems associated with inter-institutional differences, resulting cost data may be more difficult to interpret by administrators of individual institutions, and, therefore, less popular. In addition, use of standardized per unit cost estimates based on RCCs from one or more institutions can often alleviate the problem of inter-institutional differences. Shwartz et al 15 directly compare RVU-and RCC-estimated costs and find when comparing costs of individual patients, RCC-derived costs were not similar to RVU-derived costs. On the other hand, when comparing average costs for a DRG, RCC-estimated costs were within 10% of RVU-estimated costs. In addition, RCC-estimated costs were also similar to RVU-estimated costs for between hospital comparisons.
Time horizon
Ideally, a study's time horizon will include the length of time during which the majority of costs and/or benefits of a treatment are realized. In reality this 'standard' is often difficult to implement. Patients are difficult to follow once they are no longer under the care of the original physician or hospital. Researchers who cannot follow their patients for reasonable time periods should acknowledge this limitation and discuss its potential impact on study conclusions.
Currency conversion
Studies generally report costs in the currency of the study, introducing inter-country differences. This heterogeneity makes comparison of study results difficult and limits applicability of the results to those researchers who appreciate the value of the local currency. Since most studies already report costs in US dollars, an important standardization would be for all studies to report costs in US dollars in addition to, or instead of, the local currency presentation.
Discounting
It is standard in economic analyses to discount future costs to a common metric when costs are incurred over more than 1 year. This adjustment specifically acknowledges society's rate of time preference. In calculating the costs of a treatment, researchers must take into consideration that importance of time -ie the fact that incurring an expense of $100 today is not the same as incurring that cost 1 year from now since society would rather incur that cost 1 year from now. For example, if society is indifferent between incurring a cost of $100 today and incurring a cost of $103 1 year from now (even if the purchasing power were identical), the rate of time preference is 3%. This 3% figure should be used to discount all future costs to the present when comparing costs of two or more treatments. This time preference adjustment is especially important when the costs of treatments differ over time. Discounting should not be confused with inflation adjustments which account for changes in purchasing power. Inflation adjustments should also be made to provide consistent cost estimates. Although there is little theoretical basis for the selection of any particular rate of time preference, Weinstein et al 7 recommend the use of both 3% and 5% because (1) evidence on the real (inflation-adjusted) interest rate indicates that society's rate of time preference falls in this range, and (2) use of common values will enhance comparability of cost-effectiveness study findings. Table 2 presents a comparison of SCT cost studies based on the framework of Table 1 . The studies presented in Table 2 were published between 1989 and 1997 and are in (roughly) chronological order. A number of common elements can be found in most of the studies. First, as noted earlier, all of the studies limit analyses to direct medical Since 'Economic importance' is presumed here, we will not present data on whether or not the authors explicitly considered this in their paper. b AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; SAA = severe aplastic anemia; SCI = severe combined immunodeficiency; ALL = acute lymphocytic leukemia; NHL = non-Hodgkin's lymphoma. costs. While some explore quality of life after SCT, none of them measure direct non-medical costs.
A review of the literature
Most of the studies in Table 2 are based on relatively small sample sizes. With the exception of Bennett et al 19 and Hartmann et al, 24 studies included 80 patients or fewer. These small samples, primarily driven by the 'cost' of obtaining cost data, limit the power of statistical analyses and make all but the most basic stratifications (ie procedure, disease) almost impossible.
It is noteworthy that most of the more recent studies are cost-minimization rather than cost-effectiveness studies. This trend may reflect a desire to get useful (and recent) data into publication before outcome data are available. Unfortunately, the speed with which SCT technology is changing sometimes precludes waiting for long-term follow-up data. By the time good outcome information is available, the profession may be using completely different types of procedures. Table 2 also highlights the heterogeneity of approaches for examining SCT costs. Different types of modeling take advantage of different types (and quality) of data. Different time horizons are selected based on data availability and, potentially, study funding. Different approaches to uncertainty are employed ranging from no consideration of uncertainty to sophisticated predictions of survival rates and costs. Much of this heterogeneity is appropriate, as analyses and approaches must build on the strength of the data and of the investigators. However, some common approaches and analyses would facilitate comparison of study results.
Dufoir et al 18 present a relatively well-designed costeffectiveness study comparing costs and outcomes of three alternative therapies for AML. Although the data are relatively dated (patients were treated from 1978 to 1982), the design and issues highlighted make the paper an especially important one. Strengths of the paper include: a welldefined and important economic and clinical question; a narrowly-focused patient population (AML); increasing the likelihood of meaningful results; and long-term follow-up (5 years). The authors found that costs per additional life year saved for allogeneic bone marrow transplantation (alloBMT) and chemotherapy were similar and significantly lower than costs per additional life year saved for autologous BMT (autoBMT). These results tend to support results in the clinical literature that alloBMT is more effective than autoBMT in the treatment of AML. 25 Uyl-de Groot et al 21 also provide an example of a welldesigned economic study accompanying an important clinical trial. 26 The question addressed is narrower than that of DuFoir et al: What is the effectiveness, quality of life, and cost implication of autoBMT vs CHOP chemotherapy for slowly responding NHL patients? The strengths of the economic study include: quality of life considerations, 2 year follow-up for cost data, specific adjustments for inflation and rate of time preference, and modeling of outcomes to account for uncertainty. However, the study is also limited by uncertainty of clinical diagnosis for some of the patients.
The favorable outcome of poorly responsive patients who were treated with CHOP and the corresponding favorable cost-effectiveness profile of standard-dose chemotherapy may reflect treatment of a substantial number of patients who had necrotic masses, and not slowly responding disease. 27 In this study, while CHOP appears to be more cost-effective than autoBMT, the opposite conclusion is just as likely if the reported clinical trial results overstate the effectiveness of CHOP. The value of the economic study is critically dependent on the quality of the efficacy study. The study of Barr et al 22 is of considerable interest because it includes estimates of costs, life expectancy and quality of life. Although the sample size is small (n = 18) and issues of uncertainty are problematic, the authors highlight some interesting issues in their comparison of alloBMT vs standard therapy for AML and ALL. Specifically, these researchers point out important differences between the two diseases and their treatment. While alloBMT is considerably more expensive than standard therapy for AML, the outcomes are also considerably better in terms of both life years and quality-adjusted life years (QALYs). For ALL, on the other hand, alloBMT and standard therapy have similar expenses and outcomes. The authors correctly point out that these issues should be explored more fully with larger sample sizes, but that clinicians presented with these results found them quite plausible. Barr et al 22 also point out the importance of length of follow-up and assumptions regarding the life expectancy of patients beyond the follow-up period. The authors find the incremental cost per life year gained for AML to be $29 200, based on a 5 year survival. When the authors assume that patients who have survived at least 5 years have a normal life expectancy (an additional 35 years), the cost per life year (discounted) falls to $6900, making BMT more cost effective than most procedures or treatments evaluated to date in the literature.
The parameters for what is considered cost effective are still the subject of some debate. Laupacis et al 28 present one framework for categorizing 'cost-effectiveness': Technologies that cost less and are more effective are clearly cost effective (Grade A). Those that cost more and are less effective are clearly not cost effective (Grade F). In the middle ground (cost more, more effective), the authors propose three grades: incremental cost effectiveness ratio (ICE) р$20 000 (Grade B), ICE between $20 000 and $100 000 (Grade C) and ICE у$100 000 (Grade D). While it is unlikely that 5 year survivors of AML have normal life expectancies, the two estimates ($29 200 and $6900) provide upper and lower bounds on the incremental cost effectiveness of BMT.
Smith et al 23 and Hartmann et al 24 present some of the most recent data on costs of autologous BMT and peripheral blood SCT (PBSCT). The strengths of these studies include: the randomized, controlled trial design, the timeliness of the data, and the high level of detail presented. These papers represent some of the first efforts to provide extremely disaggregated cost data. While such an approach requires considerable effort, the usefulness of the data for clinicians and administrators increases dramatically. As Smith et al 23 point out, '. . . . economic implications of these techniques on any institution can be ascertained by comparing the institution's own resource utilization and costs with those reported in (our) study.' Smith et al 23 find that autologous PBSCT costs less than autologous BMT ($45 792 vs $59 314) in the treatment of patients with Hodgkin's and non-Hodgkin's lymphoma. Hartmann et al 24 report significantly lower costs of autologous SCT for lymphomas and solid tumors, with costs (in 1992 dollars) ranging from $21 688 to $26 136. Table 3 provides a summary of the results of each of the studies discussed in Table 2 , with costs converted to 1992 US dollars.
With the exception of Welch and Larson, 2 SCTs (and at least some follow-up care) are found to cost less than $100 000. Costs seem to vary by treatment type (allo vs auto, BMT vs PBSCT) and by disease. Dufoir et al 18 present evidence that alloBMT is cheaper than autoBMT for AML. Smith et al 23 find that autoPBSCT is cheaper than autoBMT for HD and NHL. Several studies provide data on the costs of alloBMT for AML, with costs generally ranging from $46 232 to $85 041 (in 1992 dollars). 16, 18, 22 This range omits data presented by Welch and Larson 2 which is relatively old (1978) (1979) (1980) (1981) (1982) , data from ViensBitker et al 16 which is based on hypothetical patients, and data from Beard et al 17 and Hartmann et al 24 which is much lower than any other estimates. Three studies provide information on the costs of autoSCT for non-Hodgkin's lymphoma, with costs ranging from $34 447 to $76 285 (in 1992 dollars). 19, 21, 23 Table 3 calls attention to the fact that very few studies address costs per life year and costs per QALY for various types of SCT. In general, studies find reasonably acceptable cost per life year and QALY (ie costs which are within the range of those found for other medical procedures), although it is clear that cost estimates depend critically on the assumptions made regarding life expectancy beyond the usual 5 year time horizon. Data on the long-term survival patterns of SCT survivors, including downstream costs of secondary metastatic disease or relapse, is critically needed. Unfortunately, the rapid evolution of SCT technology makes the timely production of relevant information very difficult. Clearly, however, increased downstream costs and/or reduced survival will reduce the incremental cost effectiveness of SCT.
Additional issues for consideration in SCT cost studies
Sections 1 and 2 provide a detailed discussion of a number of 'standardization' issues which appear in almost all cost studies. This section is devoted to a number of additional issues which should be considered when conducting SCT cost studies. These issues are not ones of 'standardization'; standardization implies that a norm or standard can be developed to facilitate the comparison of cost studies. The issues we discuss here are ones which should be considered, discussed, and accounted for. Researchers and readers must weigh study differences when considering the value/importance of study findings.
Technological change
Fortunately for cancer patients, the rate at which clinicians are improving the knowledge and treatment of many diseases is quite rapid. The impact of technological change on costs can be positive or negative. Since stem cell transplan- tation is conducted in conjunction with other treatments, including chemotherapy, radiotherapy, antibiotics, growth factors, antivirals and antifungals, it is imperative that researchers document the 'state of technology' when conducting cost studies. Only with careful documentation can comparisons be made across studies, populations and diseases. A good example of this issue is the use of growth factors, either for mobilizing stem cells prior to collection or promoting engraftment following reinfusion. Some clinicians believe that the benefits of growth factors are significant and use them extensively. Since these products are quite expensive, it is extremely important to document use of these products when evaluating costs and outcomes.
Learning curve effects
In addition to effects of technological change, Bennett et al 29 presented evidence that some centers can significantly improve outcomes and lower costs over time due to experience with a given technology. The authors investigated this 'learning curve phenomenon' for autologous SCT for Hodgkin's disease and non-Hodgkin's lymphoma from 1987 to 1991 at the University of Nebraska Medical Center. Mean costs for autologous SCT for both diseases decreased over the 5 year period (Hodgkin's disease: $96 000 to $55 000; non-Hodgkin's lymphoma: $91 000 to $74 000). The authors also noted a steady and significant reduction in in-hospital mortality rates over this period. For patients with Hodgkin's disease, mortality rates decreased from 20% in 1987 to 0% in 1991. For patients with non-Hodgkin's lymphoma, the mortality rate decreased from 29% in 1987 to 4% in 1991. The authors also investigated the incremental effect of experience on mortality. After controlling for differences in clinical factors, logistic regression predicted that patients receiving the first 30 SCTs for Hodgkin's disease had a 20% chance of dying. This decreased to a 5% chance after 178 cases. Patients with non-Hodgkin's lymphoma had a 33% chance of dying after 14 cases, which decreased to a 5% chance after 149 cases.
Bennett et al 30 found further support for the learning curve hypothesis when examining cross-sectional data from six institutions located within and outside of the USA. Four of the six centers achieved significant cost savings with the use of growth factors (GM-CSF), while two centers had higher costs with growth factor use. After completion of the study, the latter two centers subsequently shortened mean length of stay for GM-CSF patients by 1 week (a time period comparable to the four centers demonstrating a cost savings). These data further emphasize the importance that researchers must place on the experience of a treatment center when investigating effectiveness, costs and cost-effectiveness.
Inter-institutional differences
A related, but separate issue is that of inter-institutional differences. As discussed previously, costs of SCT can differ widely among institutions for many reasons (eg differences in cost attribution methods, efficiency, market conditions). In addition, there may be significant differences in clinical practice. Although clinical trial protocols and common training programs attempt to establish similarities in treatment patterns, significant differences exist among centers in the treatment of similar patients. For example, some hospitals substitute outpatient care for inpatient stays at the beginning and end of a patient's SCT. Such changes may significantly reduce direct medical costs. The ability to make this change, however, depends critically on factors such as the proximity of the patient's residence or the presence of a nearby facility with the capability of handling non-acute patients. Any cost/cost-effectiveness study should, at a minimum, attempt to identify any inter-institutional differences in treatment patterns which could significantly affect the efficacy or costs of the intervention in question. In addition, when estimating costs for patients treated at institutions making extensive use of outpatient care, researchers must be very careful to obtain similarly accurate and detailed utilization and cost information from both the outpatient as well as the inpatient settings.
Conclusion
Estimates of the costs and cost-effectiveness of SCT are still preliminary, and for unrelated donor transplants there is no available information. Studies from the USA and Europe suggest that allogeneic (HLA-identical sibling) and autologous SCT compare favorably with the cost per life year/quality-adjusted life year of other medical procedures, but few of these studies include large numbers of patients or distinguish specific diseases. Also, advancements in technology and medical practice may make many of the current studies obsolete. The challenge for researchers in this field is to analyze information in a timely enough manner to influence clinical practice.
Based on the results of the described studies, a strong foundation has been established for analyses of cost and cost-effectiveness for SCT. Key factors in conducting a thorough analysis have been determined to include: long-term follow-up of patients (greater than the 3-4 month periods included in most published studies) to determine the full benefits of SCT, careful documentation of adjuvant treatments administered with SCT, determination of institutional 'learning curve' effects, and assessments based on disease type (allowing for the possibility that SCT for different diseases may have very different cost and clinical efficacy results).
The research methodology is also being developed to provide results in a timely and more cost-effective manner. Many clinical trials now include analysis of cost-effectiveness as well as clinical efficacy. Also, as hospitals and physician groups adopt advancements in information technology, sophisticated and comprehensive information systems to track outcomes and costs are being designed. The databases that will be available in the future promise to provide more timely and accurate answers to the economic questions asked by clinicians and policy makers.
